Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 75,1 M
EBIT 2018 -3,25 M
Net income 2018 -14,7 M
Debt 2018 70,4 M
Yield 2018 -
Sales 2019 97,2 M
EBIT 2019 8,33 M
Net income 2019 -3,41 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 3,37x
Capi. / Sales2019 1,88x
Capitalization 183 M
More Financials
Company
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products.It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets.The company was founded by Jane E. Hager in... 
Sector
Pharmaceuticals
Calendar
05/08 | 06:50pmPresentation
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
04/17Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.0..
GL
04/06TELIGENT : Announces FDA Approval of Ciclopirox Shampoo, 1%
AQ
04/06Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%
GL
03/27R1 Appoints Alex Mandl as Lead Director
AQ
03/265 TOP NASDAQ BIOTECH STOCKS : Teligent on the Top
AQ
03/23TELIGENT INC : Blog Exposure - FDA Approved Teligent’s Halobetasol Propionate Oi..
AC
03/21TELIGENT : Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
AQ
03/21TELIGENT : Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
AQ
03/19TELIGENT : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
03/16TELIGENT : Announces Fourth Quarter and Year End 2017 Results
AQ
More news
Sector news : Pharmaceuticals - NEC
08:48aSHIRE : Drugmaker Shire to Support Latest Offer From Takeda -- WSJ
DJ
08:22aTAKEDA PHARMACEUTICAL : Statement -2-
DJ
08:22aTakeda Pharmaceutical Company Ltd Statement regarding Shire plc
DJ
08:16aSHIRE PLC SHIRE PLC : Shire Announces Revised -3-
DJ
08:16aSHIRE PLC SHIRE PLC : Shire Announces Revised -2-
DJ
More sector news : Pharmaceuticals - NEC
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,50 $
Spread / Average Target 59%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Damian Finio Chief Financial Officer & Secretary
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI183
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571